Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression

Author： Leuchter Andrew Morgan Melinda Cook Ian Dunkin Jennifer Abrams Michelle Witte Elise

Publisher： Springer Publishing Company

ISSN： 0033-3158

Source： Psychopharmacology, Vol.177, Iss.1-2, 2004-12, pp. : 15-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Paroxetine "not superior" to placebo in major depression

Inpharma, Vol. 1, Iss. 1628, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Dose–response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder

By Bech Per Kajdasz Daniel Porsdal Vibeke

Psychopharmacology, Vol. 188, Iss. 3, 2006-10 ,pp. : 273-280

Springer Publishing Company

Access to resources Recommend Favorite

The treatment of dysthymia with sertraline: a double-blind placebo-controlled trial in dysthymic outpatients without major depression

By Guelfi J.D. Wiseman R.L.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 289-290

Elsevier

Access to resources Recommend Favorite

Adaptive randomization in clinical trials: a placebo compromise

By Wood A. Faries D. Heiligenstein J.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 257-258

Elsevier

Access to resources Recommend Favorite

Catecholaminergic Strategies for the Treatment of Major Depression

Current Drug Targets, Vol. 7, Iss. 2, 2006-02 ,pp. : 149-158

Bentham Science Publishers

Access to resources Recommend Favorite